High-dose cisplatin in advanced head and neck cancer
dc.contributor.author | Takasugi, Bonnie J. | en_US |
dc.contributor.author | Wolf, Gregory T. | en_US |
dc.contributor.author | Kudla-Hatch, Vickie | en_US |
dc.contributor.author | Baker, Shan R. | en_US |
dc.contributor.author | Forastiere, Arlene A. | en_US |
dc.date.accessioned | 2006-09-11T18:22:25Z | |
dc.date.available | 2006-09-11T18:22:25Z | |
dc.date.issued | 1987-04 | en_US |
dc.identifier.citation | Forastiere, Arlene A.; Takasugi, Bonnie J.; Baker, Shan R.; Wolf, Gregory T.; Kudla-Hatch, Vickie; (1987). "High-dose cisplatin in advanced head and neck cancer." Cancer Chemotherapy and Pharmacology 19(2): 155-158. <http://hdl.handle.net/2027.42/46916> | en_US |
dc.identifier.issn | 1432-0843 | en_US |
dc.identifier.issn | 0344-5704 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/46916 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=3568273&dopt=citation | en_US |
dc.description.abstract | In 22 patients with advanced squamous cell carcinoma of the head and neck we evaluated the efficacy and toxicity of 200 mg/m 2 cisplatin administered in 3% NaCl with vigorous hydration. Six patients had previously untreated stage IV disease and 16 patients had recurrent disease, including eight with prior chemotherapy including low-dose cisplatin and carboplatin. Cisplatin was administered as a brief infusion, either 40 mg/m 2 /day × 5 or 50mg/m 2 /day × 4, every 28 days. Objective responses were observed in 16 of 22 (73%) patients, including 5 of 6 (83%) previously untreated patients and 11 of 16 (69%) patients with recurrent disease. This included two comoplete responses, one confirmed pathologically. Fifty-seven courses of drug were administered and toxicity was monitored with serial creatinine clearance determinations, audiograms, and sensorimotor exams. Neuropathy and ototoxicity were dose-limiting and led to the stopping of treatment in 12 of the 16 responders after one to four courses (median three courses). Only two responding patients continued treatment until disease progression occurred at 3 and 4 months after achieving maximum response. Acute, transient nephrotoxicity occurred in four patients; two were retreated. Moderate myelosuppression occurred in all patients but was not treatment-limiting. For most patients the maximally tolerated number of courses was three. The median survival time was 33.5 weeks for recurrent disease patients, 108 weeks for newly diagnosed patients. This regimen is not recommended for the palliation of recurrent disease. However, the very high response rate suggests that high-dose cisplatin may have a useful role in induction or adjuvant chemotherapy regimens. | en_US |
dc.format.extent | 463294 bytes | |
dc.format.extent | 3115 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Springer-Verlag | en_US |
dc.subject.other | Oncology | en_US |
dc.subject.other | Cancer Research | en_US |
dc.subject.other | Biomedicine | en_US |
dc.subject.other | Pharmacology/Toxicology | en_US |
dc.title | High-dose cisplatin in advanced head and neck cancer | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Radiology | en_US |
dc.subject.hlbsecondlevel | Chemistry | en_US |
dc.subject.hlbsecondlevel | Chemical Engineering | en_US |
dc.subject.hlbsecondlevel | Biological Chemistry | en_US |
dc.subject.hlbtoplevel | Engineering | en_US |
dc.subject.hlbtoplevel | Science | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Otolaryngology, Head and Neck Surgery, University of Michigan Hospital, Ann Arbor, MI, USA; Veterans Administration Medical Center, Ann Arbor, MI, USA | en_US |
dc.contributor.affiliationum | Department of Internal Medicine, Division of Hematology/Oncology, The University of Michigan Hospital, Ann Arbor, MI, USA; Oncology Section (111E) VA Medical Center, 2215 Fuller Rd, 48105, Ann Arbor, MI, USA | en_US |
dc.contributor.affiliationum | Department of Internal Medicine, Division of Hematology/Oncology, The University of Michigan Hospital, Ann Arbor, MI, USA | en_US |
dc.contributor.affiliationum | Department of Otolaryngology, Head and Neck Surgery, University of Michigan Hospital, Ann Arbor, MI, USA; Veterans Administration Medical Center, Ann Arbor, MI, USA | en_US |
dc.contributor.affiliationum | Department of Internal Medicine, Division of Hematology/Oncology, The University of Michigan Hospital, Ann Arbor, MI, USA | en_US |
dc.contributor.affiliationumcampus | Ann Arbor | en_US |
dc.identifier.pmid | 3568273 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/46916/1/280_2004_Article_BF00254569.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1007/BF00254569 | en_US |
dc.identifier.source | Cancer Chemotherapy and Pharmacology | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.